GLP-3 (Retatrutide)
Metabolic · 10 mg fill · Research Peptide
A triple GIP, GLP-1 and glucagon receptor agonist, investigated in multi-receptor incretin signaling research.
Overview
Supplied under the label GLP-3, this compound is retatrutide: an investigational synthetic peptide that agonises three receptors — GIP, GLP-1 and glucagon (GCGR). It is not approved by any regulatory agency for any indication. Structural work published in 2024 describes how a single sequence engages all three receptor conformations. Supplied lyophilized for in-vitro research use.
Specifications
- Composition
- Retatrutide · triple GIP/GLP-1/glucagon receptor agonist (investigational, lipidated peptide)
- Form
- Lyophilized powder
- Vial Size
- 10 mg
- Purity
- >99% (HPLC)
- Reconstitution
- Bacteriostatic water
- Storage
- −20°C · protect from light
- Documentation
- Batch-specific COA
Research applications
- Triple-agonist receptor-binding assays
- GCGR, GIPR and GLP-1R signaling comparison
- Structural and receptor-conformation studies
- Comparative incretin-analog research
For research use only. This product is intended for laboratory and educational research purposes only. It has not been evaluated by the FDA and is not for human or veterinary consumption, diagnosis, treatment, or cure of any condition.
View in catalogOrdering, vial options and the cart live in the catalog view.